Lub ntiaj teb kev sib zog ntawm Hom 2 Ntshav Qab Zib Mellitus (T2Dm) tseem nce ntau dua 140 lab tus neeg mob hauv Suav teb ib leeg. Cov kab mob kev tswj hwm ntsib cov ntshav uas tsis txaus ntawm cov ntshav roj hmab uas tsis txaus thiab cov teeb meem hnyav ntawm cov teeb meem. Cov qauv ib txwm muaj yog maj mam hloov mus rau ib qho kev tswj hwm ntau yam kev tsom ntsoov tsom rau ntshav qab zib, qhov hnyav, thiab plawv kev noj qab haus huv. Hauv cov ntsiab lus no,tirzepatide, raws li lub ntiaj teb thawj zaug gip / gp receptor agonist, yog rov kho cov toj roob hauv pes ntawm cov ntshav qab zib thiab cov txiaj ntsig kev hloov tshiab.
|
|
1.Txoj kev tshwj xeeb (hauv Tshuag) |
Kev Tsim Hluav Taws Xob
|
Dual qhib ntawm gip / gpp-1 receptors TIRPERPTIONIDES PANTIONS PERMICAL TXOJ KEV TSHWJ XEEB LOS NTAWM IB TUG HLOOV RAU GIP THIAB GLP-1 RECEPTORS: 1) glp {- 1 txoj kev: Txhawb nqa cov khoom tso tawm insulin nyob rau hauv ib qho qabzib tso tawm, uas txwv tsis pub muaj 40%, thiab nce siab. 2) GIP ດ່ວນ: txhim kho cov tshuaj tiv thaiv insulin hauv cov nqaij mos, txhawb nqa cov rog postprandial hauv cov rog dawb, thiab txo cov roj tso dej ectopic los ntawm ntau dua 30%. Cov kev tshawb fawb preclinical qhia tau hais tias ob lub chaw ua haujlwm muaj txiaj ntsig zoo tshaj plaws yog 2.3 lub hom phiaj - poob nyhuv yog 1.8 npaug. |
|
|
|
Cov Kev Tswj Xyuas Cov Nomet Netabolic Nom Tirpooliaide regulates metabolism hauv ob lub central central {}}} pipheral txoj hauv kev: 1) Cov leeg nruab nrab: Cov cai ntawm hypothalamic arcapping nucleus los txo cov neuropeptide y (NPY) hais tawm los ntawm 15-20%. 2) Cov nqaij daim ntaub so ntswg sib dhos Qhov ntau -} theem kev tswj hwm kev siv tshuab ua rau nws ua tiav qhov kev txhim kho hnyav thaum txo cov ntshav qab ntshav qab zib. Kev tshawb fawb yooj yim tau lees tias Telbobride tuaj yeem ua siab loj tau ua rau glut4 qhia nyob rau hauv adipocytes thiab txhim kho insulin signaling. |
Kev ua tau zoo ntawm tirzepatide nyob rau hauv kev kho mob ntshav qab zib hom 2
(1) qhov cuam tshuam loj dua
Ntau lub chaw kuaj mob tau txais kev paub tseeb tias qhov kev cuam tshuam zoo tshaj plaws ntawm tirzepatide nyob rau hauv kev kho mob ntshav qab zib hom 2. Nyob rau hauv lub surpass series ntawm kev tshawb fawb, tirzepatide qhia muaj peev xwm muaj peev xwm txo qis glycated hemoglobin (HBA1C). Piv txwv li, nyob rau hauv lub surpass-1 kawm, 92% ntawm tirzepatide cov neeg koom tau HBA1C qib qis dua 7%; Ntau dua 52% ntawm cov neeg mob muaj HBA1C qib qis dua 5.7%, thaum tsuas yog 1% ntawm cov ntaub ntawv ntawm cov ntaub ntawv tau ua tiav qib no. Qhov no qhia tau tias tirzepatide tuaj yeem txhim kho cov neeg mob glycemic tswj, enterping ntau cov neeg mob kom ua tiav glycemic cov hom phiaj.
(2) qhov hnyav zoo dua-} poob cov teebmeem
Ntxiv rau kev txo cov ntshav qab zib, Tirzepatide kuj ua rau pom qhov hnyav zoo tshaj {{}} poob cov teebmeem. Kev pham yog qhov pheej hmoo loj rau hom 2 mob ntshav qab zib, thiab poob phaus yog qhov tseem ceeb rau kev txhim kho cov ntshav ntshav qab zib thiab txo cov kev pheej hmoo ntshav qab zib thiab txo cov kev pheej hmoo ntshav. Nyob rau hauv surmount -} 1 kawm, cov neeg mob tau ua tiav qhov ua tiav qhov hnyav hnyav ntawm 22.9%, thaum pab pawg placebeb tsuas yog poob 2.1%. Qhov kev kawm CN SURMount ua hauv cov pej xeem Suav kuj tau pom tias tus neeg mob kom poob qis dua 52 lub lis piam poob ntawm 11.3% mus rau 15.1%. Tshaj 85% ntawm cov neeg mob ua tiav qhov hnyav hnyav, nrog lub poob phaus ntawm 85.8% rau 87.7%. Qhov hnyav hnyav poob phaus zoo tshaj plaws ua rau tirzepatide ib qho tshwj xeeb hauv kev kho mob ntshav qab zib hom 2.
(3) txhim kho cov insulin rhiab
Ntev -} siv ntawm tirzepatide insulin rhiab heev thiab ua kom muaj kev tiv thaiv insulin. Hauv txoj kev kawm tseem ceeb, 117 tus neeg mob uas muaj cov ntshav qab zib hom 2, tau txais tirzepatide 15 mg, semaglutide 1 mg, lossis placebo, feem. Insulin rhiab tau soj ntsuam siv lub siab - insulin euglycemic clamp kuaj. Thaum kawg ntawm 28-lub lim tiam kev kawm, ob pawg tirzepatide thiab semaglutide qhia qhov nce ntxiv rau cov kev cuam tshuam rau ib pab dej ntau dua li cov pab pawg semagloutide. Qhov no qhia tau tias Tirzepatide tuaj yeem txhim kho cov insulin rhiab heev, thiab pab lub cev ua kom muaj txiaj ntsig zoo rau cov ntshav ntshav qab zib.
(4) Kev Tiv Thaiv Cardiovascular
Cov neeg mob uas muaj ntshav qab zib hom 2 muaj qhov muaj feem yuav muaj kev pheej hmoo ntawm cov tshuaj tiv thaiv kab mob plawv, yog li cov hlab ntsha tiv thaiv cov tshuaj muaj kev txhawj xeeb zoo heev. The SURPASS-CVOT study is the first global large-scale head-to-head study comparing the cardiovascular outcomes of two incretin-based drugs, comparing tirzepatide with the GLP-1 receptor agonist dulaglutide, which muaj cov teebmeem plawv kev cuam tshuam. Cov txiaj ntsig kev kawm tau pom tias Tirzepatide tsis - ua rau muaj kev pheej hmoo ntawm cov kev pheej hmoo ntawm cov kev pheej hmoo ntawm cov kev pheej hmoo ntawm cov kev pheej hmoo ntawm cov kev pheej hmoo ntawm cov kev pheej hmoo ntawm cov kev pheej hmoo ntawm cov kev pheej hmoo ntawm cov kev pheej hmoo ntawm cov kev pheej hmoo ntawm cov kev pheej hmoo ntawm cov kev pheej hmoo loj Ib qho ntxiv, Tirzepatide qhia kev txhim kho hauv A1C, qhov hnyav, raum ua haujlwm, thiab ua txhua yam - ua rau muaj kev tuag. Qhov no qhia tau tias tsis muaj kev tiv thaiv cov ntshav qab zib thiab qhov hnyav rau cov neeg mob ntshav qab zib hom 2.
Los ntawm cov ntshav qab zib tswj kev tiv thaiv lub cev
● Kev tshaj tawm txoj kev tshawb fawb: Kev faib dua tshiab hauv Glycemic tswj thiab poob phaus
Lub ntiaj teb theem III Kev Kawm Tshaj Tawm Kev Kawm muaj 12,313 ntawm cov neeg mob uas muaj hom 2 qhov tseem ceeb ntawm Tirzepatide ntawm cov koob tshuaj sib txawv:
1) GlyciMic Control: 15mg koob tshuaj pab pawg ua tiav qhov kev txo qis hauv HBA1C ntawm 2.37%, nrog 89% ntawm cov neeg mob ncav cuag cov hom phiaj (<7%), representing an additional 0.5% reduction compared to the semaglutide group.
Kev tswj qhov hnyav: Qhov hnyav hnyav ntawm 13.1%, nrog 46% ntawm lawv lub cev poob qis, thiab 28% txo hauv visceral rog.
2) Kev txhim kho metabolic: cov roj (cholesterister tag nrho cov roj (triglycerides txo qis los ntawm 25%
Lub sundwa - ap {{}}}} Cov neeg muaj kev cuam tshuam rau hauv Suav teb: 10% qis dua ntawm cov neeg HBA1C, thiab 10% qis dua ntawm cov pej xeem
● Surmount-1 Kev Kawm: Kev Tiv Thaiv Kev Tiv Thaiv Ntshav Qab Zib
Hauv ib peb {- xyoo kawm hom neeg rog nrog cov neeg ua ntej, tirzepatide qhia nws cov peev xwm tiv thaiv:
1) Txo cov kev pheej hmoo: piv nrog cov ntshav qab zib hom 2% (hr}}, 95% CI: 0.02-0.19).
2) Kev Txhawb Nqa Lub Cev Poob Haujlwm Qhov hnyav
Txhim kho cov cim metabolic: Kev yoo ntshav qab zib txo los ntawm 2.1MMol / L, Insulin Refension Index (Home {1%, thiab 78% ntawm daim siab enzyme qib rov qab los li qub.
Surpass {- Cvot Kev Kawm: Kev Tiv Thaiv Kev Tiv Thaiv Kev Tiv Thaiv Cardiovascular
Thawj qhov kev ua yeeb yam thoob ntiaj teb kev kawm ntawm ib qho intetin - Raws cov tshuaj paub:
Tseem ceeb kawg: tsis - tsis muaj peev xwm piv rau dulaglutide rau dulaglutide (hr}}
Cov kev tiv thaiv lub raum: Kev poob qis txhua xyoo hauv EGFL qeeb los ntawm 32%, thiab qhov tshwm sim ntawm proteinuria poob qis los ntawm 21%, ncua kev ua kom muaj kev vam meej ntawm cov ntshav qab zib nephotropathy.
Cov tshuab kuaj mob: Txhim kho Myocardial lub zog me me me me, txo cov plaedosclerotic plaque ntim los ntawm 19%, thiab txhim kho vascular endothelial ua tau los ntawm 28%.
Tag
Tirerptide, raws li tshiab dual agonist ntawm tus gip / glp {}} 1 receptor, qhia qhov tseem ceeb hauv kev ua haujlwm ntawm kev ua thiab tseem ceeb hauv chaw kho mob. Nws cov ntshav qab zib tseem ceeb - kev tiv thaiv thiab kev tiv thaiv kab mob plawv, muab hom 2 kev xaiv ntshav qab zib ntau dua.
Raws li cov kev sim tshuaj ntsuam xyuas tau ua thiab tshawb fawb, cov lus qhia kom nthuav dav ntxiv, nrog kev txhawb nqa tus kab mob raum, thiab kev txhawb nqa apnea syndrome, thiab lub siab ua tsis tiav. Nyob rau yav tom ntej, tirerceptide yog poised los ua ib qho ntawm cov tshuaj tseem ceeb rau kev kho mob ntshav qab zib hom 2, coj kev noj qab haus huv thiab cia siab rau ntau tus neeg mob.
Txawm li cas los xij, peb yuav tsum lees paub tias cov tshuaj kho tsuas yog ib feem ntawm kev tswj hwm cov ntshav qab zib hom ntshav qab zib Hom 2. Thaum siv Tilapeptide, cov neeg mob yuav tsum nquag txhim kho kev ua haujlwm zoo, nrog kev tswj hwm kev tawm dag zog, ua kom muaj kev haus haus cawv, kom ua tiav cov txiaj ntsig zoo dua. Ib qho ntxiv, cov kws kho mob yuav tsum tsim kho tus kheej cov phiaj xwm kev kho mob raws li tus neeg mob tshwj xeeb los xyuas kom muaj kev nyab xeeb thiab ua haujlwm ntawm cov tshuaj.
Hauv cov ntsiab lus, kev qhia ntawm Tirzepatide tau coj kev sib tawg tshiab hauv kev kho mob ntshav qab zib hom 2. Peb muaj txhua qhov laj thawj kom ntseeg tau tias muaj kev tshawb fawb txog kev kho mob, kev kho mob hom tseem ceeb dua, kev tiv thaiv cov neeg mob kev noj qab haus huv.